GILD - Gilead Sciences Inc Year-over-year net earnings per share growth for the last 12 months

Corporate company logo of Gilead Sciences, Inc. (GILD)

Historical quarterly EPS growth demonstrates profit dynamics as Gilead Sciences, Inc. (GILD) pivots toward CAR-T therapy and oncology, with -19.80 reflecting the most recent metric value. Leadership in virology is sustained by recruiting top scientists and providing high compensation. Business development relies on strategic partnerships with startups and joint clinical trials.

gilead.com (GILD) Year-over-year net earnings per share change for the last twelve months: for the period 07/04/2022 - 11/18/2026

Summary analytical data breakdowns for gilead.com (GILD)

- market value and analyst target forecast:
- market capitalization statistics:
Fundamental valuation:gilead.com - GILD
Flagship merchandise of Gilead Sciences, Inc.

For Gilead Sciences, Inc. (GILD), profit dynamics determine the effectiveness of the transition from HIV therapy dominance to the oncology segment. This metric is calculated as the percentage change in net earnings per share compared to the same period last year. By analyzing this quarterly earnings per share chart, investors can assess the real speed of capital growth. A positive trend confirms successful portfolio diversification via Trodelvy. The stability of this metric guarantees the sustainability of dividend payments.

Analysis of competing companies

Cidara Corp (CDTX) - Year-over-year earnings per share growth for the last twelve months|Novavax, Inc. - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CVAC|Quarterly EPS earnings growth valneva.com|Year-over-year net earnings per share growth for the last 12 months VIR (Vir Biotechnology)|Year-over-year net earnings per share change for the last twelve months SIGA Technologies Inc|Year-over-year earnings per share growth for the last twelve months Emergent Bio EBS|Quarterly EPS earnings growth Atea Pharmaceuticals AVIR|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)